BIOMARIN PHARMACEUTICAL INC (BMRN)
US09061G1013 - Common Stock
BMRN gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. BMRN scores excellent on profitability, but there are some minor concerns on its financial health. BMRN is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! These ratings would make BMRN suitable for growth investing!
1. Profitability
1.1 Basic Checks
In the past year BMRN was profitable.
In the past year BMRN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: BMRN reported negative net income in multiple years.
Each year in the past 5 years BMRN had a positive operating cash flow.
1.2 Ratios
BMRN has a Return On Assets of 2.45%. This is amongst the best in the industry. BMRN outperforms 95.03% of its industry peers.
The Return On Equity of BMRN (3.39%) is better than 95.03% of its industry peers.
BMRN's Return On Invested Capital of 2.21% is amongst the best of the industry. BMRN outperforms 94.69% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.45% | ||
| ROE | 3.39% | ||
| ROIC | 2.21% |
ROA(3y)1.2%
ROA(5y)3.56%
ROE(3y)1.65%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 6.93%, BMRN belongs to the top of the industry, outperforming 95.72% of the companies in the same industry.
BMRN's Profit Margin has declined in the last couple of years.
The Operating Margin of BMRN (6.54%) is better than 94.86% of its industry peers.
With an excellent Gross Margin value of 78.72%, BMRN belongs to the best of the industry, outperforming 87.16% of the companies in the same industry.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.54% | ||
| PM (TTM) | 6.93% | ||
| GM | 78.72% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-46.86%
PM growth 5YN/A
GM growth 3Y3.1%
GM growth 5Y-0.03%
2. Health
2.1 Basic Checks
BMRN has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
The number of shares outstanding for BMRN has been increased compared to 1 year ago.
Compared to 5 years ago, BMRN has more shares outstanding
Compared to 1 year ago, BMRN has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 6.11 indicates that BMRN is not in any danger for bankruptcy at the moment.
BMRN's Altman-Z score of 6.11 is amongst the best of the industry. BMRN outperforms 82.19% of its industry peers.
The Debt to FCF ratio of BMRN is 21.05, which is on the high side as it means it would take BMRN, 21.05 years of fcf income to pay off all of its debts.
BMRN has a better Debt to FCF ratio (21.05) than 94.18% of its industry peers.
BMRN has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
BMRN's Debt to Equity ratio of 0.12 is on the low side compared to the rest of the industry. BMRN is outperformed by 64.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 21.05 | ||
| Altman-Z | 6.11 |
ROIC/WACC0.25
WACC8.75%
2.3 Liquidity
A Current Ratio of 2.51 indicates that BMRN has no problem at all paying its short term obligations.
With a Current ratio value of 2.51, BMRN is not doing good in the industry: 73.12% of the companies in the same industry are doing better.
BMRN has a Quick Ratio of 1.57. This is a normal value and indicates that BMRN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.57, BMRN is doing worse than 80.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.57 |
3. Growth
3.1 Past
BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 227.59%, which is quite impressive.
The earnings per share for BMRN have been decreasing by -40.67% on average. This is quite bad
Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 15.42% in the last year.
Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.16% on average per year.
EPS 1Y (TTM)227.59%
EPS 3Y-40.67%
EPS 5YN/A
EPS growth Q2QN/A
Revenue 1Y (TTM)15.42%
Revenue growth 3Y9.15%
Revenue growth 5Y10.16%
Revenue growth Q2Q20.22%
3.2 Future
The Earnings Per Share is expected to grow by 49.53% on average over the next years. This is a very strong growth
Based on estimates for the next years, BMRN will show a quite strong growth in Revenue. The Revenue will grow by 13.54% on average per year.
EPS Next Y78.12%
EPS Next 2Y72.72%
EPS Next 3Y61.93%
EPS Next 5Y49.53%
Revenue Next Year14.56%
Revenue Next 2Y14.63%
Revenue Next 3Y14.46%
Revenue Next 5Y13.54%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 96.00, the valuation of BMRN can be described as expensive.
BMRN's Price/Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 94.35% of the companies in the same industry.
BMRN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 25.25.
A Price/Forward Earnings ratio of 53.90 indicates a quite expensive valuation of BMRN.
Based on the Price/Forward Earnings ratio, BMRN is valued cheaply inside the industry as 94.35% of the companies are valued more expensively.
BMRN's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.67.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 96 | ||
| Fwd PE | 53.9 |
4.2 Price Multiples
BMRN's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BMRN is cheaper than 94.86% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, BMRN is valued cheaply inside the industry as 94.18% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 335.11 | ||
| EV/EBITDA | 64.77 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of BMRN may justify a higher PE ratio.
A more expensive valuation may be justified as BMRN's earnings are expected to grow with 61.93% in the coming years.
PEG (NY)1.23
PEG (5Y)N/A
EPS Next 2Y72.72%
EPS Next 3Y61.93%
5. Dividend
5.1 Amount
BMRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BIOMARIN PHARMACEUTICAL INC
NASDAQ:BMRN (4/24/2024, 7:00:01 PM)
Premarket: 87.7 -3.5 (-3.84%)91.2
-0.86 (-0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap17.31B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 96 | ||
| Fwd PE | 53.9 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)1.23
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.45% | ||
| ROE | 3.39% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | 6.54% | ||
| PM (TTM) | 6.93% | ||
| GM | 78.72% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.51 | ||
| Quick Ratio | 1.57 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)227.59%
EPS 3Y-40.67%
EPS 5Y
EPS growth Q2Q
EPS Next Y78.12%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)15.42%
Revenue growth 3Y9.15%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y